
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malaria | EFO_0001068 | D008288 | B54 |
| vivax malaria | EFO_0007445 | D016780 | B51 |
| falciparum malaria | EFO_0007444 | D016778 | B50 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | 1 | — | 1 | — | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | — | — | 2 | 2 | 8 | — | — | 11 |
| Hepatitis | D006505 | — | K75.9 | 1 | 1 | 6 | — | — | 8 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 1 | 6 | — | — | 8 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 3 | — | — | 3 |
| Herpes simplex | D006561 | — | B00 | — | — | 2 | — | — | 2 |
| Papillomavirus infections | D030361 | — | — | 1 | — | 1 | — | — | 2 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | — | — | 2 | — | — | 2 |
| Herpes genitalis | D006558 | EFO_0007282 | A60 | — | — | 1 | — | — | 1 |
| Hiv | D006678 | — | O98.7 | — | — | 1 | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Virus diseases | D014777 | — | B34 | — | 2 | — | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | 1 | — | — | — | 1 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | — | — | — | — | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
| Drug common name | Halofantrine |
| INN | halofantrine |
| Description | Halofantrine is a drug used to treat malaria. Halofantrine's structure contains a substituted phenanthrene, and is related to the antimalarial drugs quinine and lumefantrine. Marketed as Halfan, halofantrine is never used to prevent malaria and its mode of action is unknown, although a crystallographic study showed that it binds to hematin in vitro, suggesting a possible mechanism of action. Halofantrine has also been shown to bind to plasmepsin, a haemoglobin degrading enzyme unique to the malarial parasites.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12 |
| PDB | — |
| CAS-ID | 69756-53-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1107 |
| ChEBI ID | — |
| PubChem CID | 37393 |
| DrugBank | DB01218 |
| UNII ID | Q2OS4303HZ (ChemIDplus, GSRS) |
